Myo-Inositol

What is myo-inositol?

Inositol is a sugar alcohol with nine possible isomeric forms; myo-inositol is the most abundant in human tissue. The body synthesizes inositol from glucose, and it is also present in beans, citrus fruit, and whole grains. It is not a vitamin per se, but it functions as a precursor to important signaling molecules — most notably the second messengers used by the insulin receptor.

How myo-inositol works

When insulin binds to its receptor, an intracellular cascade involving phosphatidylinositol second messengers translates the signal into glucose uptake. In insulin-resistant tissue, this signaling pathway is impaired. Supplementing with myo-inositol — and the related D-chiro-inositol — restores those second messengers, partially correcting the signaling defect at the cellular level rather than blunting insulin output.

The mechanism is fundamentally different from metformin (which activates AMPK), berberine (also AMPK), or GLP-1 medications (which act on satiety and incretin pathways). This is why inositol stacks productively with all three.

What the evidence shows

The most consistent evidence sits in polycystic ovary syndrome (PCOS) — the prototypical insulin-resistant reproductive disorder.

• A 2017 systematic review in Trends in Endocrinology & Metabolism found myo-inositol significantly improved menstrual regularity, ovulation, and metabolic parameters in PCOS, with effects comparable to metformin and fewer side effects [1].
• A 2018 randomized trial in Gynecological Endocrinology found 2 g of myo-inositol twice daily significantly reduced fasting insulin, HOMA-IR, and free androgen index in women with PCOS [2].
• A 2022 trial in Diabetes Therapy extended these findings to non-PCOS adults with prediabetes, showing improved insulin sensitivity over 12 weeks at the same dose [3].

Evidence level: strong in PCOS and insulin-resistant women; moderate in general metabolic syndrome.

Myo-inositol for menopause and women over 40

The metabolic profile of perimenopause is, in important respects, a mirror of PCOS: rising fasting insulin, increased visceral adiposity, and a tilt toward androgenic symptoms in the context of falling estradiol. The same trials that established myo-inositol in PCOS suggest direct relevance to perimenopausal physiology.

A small 2021 randomized trial in postmenopausal women with metabolic syndrome (4 g/day for 6 months) found improvements in fasting glucose, HOMA-IR, lipid panel, and bone turnover markers. The bone signal is particularly interesting — postmenopausal bone loss has an insulin-resistance component, and inositol may address it at a mechanism level rather than after the fact.

In our internal protocols, myo-inositol is the most-paired adjunct with berberine for women who want a non-prescription metabolic stack. It also pairs well with GLP-1 medications for women whose PCOS-pattern symptoms persist into perimenopause.

Dosage used in research

The dominant evidence-based dose is 2 g of myo-inositol, twice daily (4 g/day total), often paired with 50 mg of D-chiro-inositol in a 40:1 ratio. Some trials use higher doses (4 g twice daily). Effects on insulin and androgens build over 8–12 weeks; effects on cycle regularity over 3–6 months. Discuss dosing with your provider.

Safety and interactions

Myo-inositol is exceptionally well tolerated. The most common side effect is loose stools at doses above 12 g/day — well above the therapeutic range. There are no documented serious drug interactions. It is one of the few metabolic supplements with safety data in pregnancy (used for gestational-diabetes prevention).

Where you will find it at kindr

Myo-inositol is in our MetaPrime and GLP-1 Turbo stacks, and is one of our standard adjuncts for women whose metabolic and menstrual symptoms predate menopause. For a deeper protocol view see the menopause supplements guide.

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026